# US 2021/0069256 A1 · Universal donor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069256 A1
- Document ID: US20210069256A1
- Status: Published application
- Kind: A1
- Application number: 17/013,143
- Filed: 2020-09-04
- Published: 2021-03-11
- Earliest claimed: 2019-09-05
- Assignees: Crispr Therapeutics AG
- Applicants: Crispr Therapeutics AG
- Inventors: ALIREZA REZANIA; REBECA RAMOS-ZAYAS
- Web page: https://patentgrep.com/patent/US20210069256A1

## CPC

- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 38/1709: {from mammals}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- C12N 5/0678: {Stem cells; Progenitor cells; Precursor cells}
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 5/16: Animal cells
- C12N 15/85: for animal cells
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

## Claims

### Claim 1

A universal donor cell comprising (a) a nucleotide sequence encoding programmed death-ligand 1 (PD-L1) inserted within or near a gene encoding beta-2 microglobulin (B2M) and (b) a nucleotide sequence encoding HLA class I histocompatibility antigen, alpha chain E (HLA-E) inserted within or near a gene encoding thioredoxin interacting protein (TXNIP), wherein the universal donor cell expresses PD-L1 and HLA-E and has disrupted expression of B2M and TXNIP, and the universal donor cell has increased immune evasion and/or cell survival compared to a control cell.

### Claim 2 (depends on 1)

The universal donor cell of claim 1, wherein the control cell is a wild type cell or a cell that does not comprise the inserted nucleotide sequence.

### Claim 3 (depends on 1)

The universal donor cell of claim 1, wherein the disrupted expression of B2M comprises reduced or eliminated expression of B2M and the disrupted expression of TXNIP comprises reduced or eliminated expression of TXNIP.

### Claim 4 (depends on 1)

The universal donor cell of claim 1, wherein the nucleotide sequence encoding PD-L1 consists essentially of SEQ ID NO: 11.

### Claim 5 (depends on 1)

The universal donor cell of claim 1, wherein the nucleotide sequence encoding HLA-E comprises a sequence encoding a HLA-E trimer comprising a B2M signal peptide fused to an HLA-G presentation peptide fused to a B2M membrane protein fused to HLA-E without its signal peptide.

### Claim 6 (depends on 5)

The universal donor cell of claim 5, wherein the sequence encoding the HLA-E trimer consists essentially of SEQ ID NO: 55.

### Claim 7 (depends on 1)

The universal donor cell of claim 1, wherein the nucleotide sequence encoding PD-L1 is operably linked to an exogenous promoter, and the nucleotide sequence encoding HLA-E is operably linked to an exogenous promoter.

### Claim 8 (depends on 7)

The universal donor cell of claim 7, wherein the exogenous promoter is a CAG promoter.

### Claim 9 (depends on 1)

The universal donor cell of claim 1, wherein the cell is a stem cell.

### Claim 10 (depends on 9)

The universal donor cell of claim 9, wherein the stem cell is an embryonic stem cell, an adult stem cell, an induced pluripotent stem cell, or a hematopoietic stem cell.

### Claim 11 (depends on 1)

The universal donor cell of claim 1, wherein the cell is a differentiated cell or a somatic cell.

### Claim 12 (depends on 1)

The universal donor cell of claim 1, wherein the cell is capable of being differentiated into lineage-restricted progenitor cells or fully differentiated somatic cells.

### Claim 13 (depends on 12)

The universal donor cell of claim 12, wherein the lineage-restricted progenitor cells are definitive endoderm cells, primitive gut tube cells, posterior foregut cells, pancreatic endoderm progenitors, pancreatic endocrine progenitors, immature beta cells, or maturing beta cells, and the fully differentiated somatic cells are pancreatic beta cells.

### Claim 14 (depends on 1)

A plurality of universal donor cells according to claim 1.

### Claim 15 (depends on 14)

The plurality of cells of claim 14, wherein at least about 50% of the cells express PD-L1 and/or at least about 50% of the cells express HLA-E.

### Claim 16 (depends on 14)

The plurality of cells of claim 14, wherein at least about 70% of the cells express PD-L1 and/or at least about 70% of the cells express HLA-E.

### Claim 17 (depends on 14)

The plurality of cells of claim 14, wherein at least about 90% of the cells express PD-L1 and/or at least about 90% of the cells express HLA-E.

### Claim 18 (depends on 14)

A population of lineage-restricted progenitor cells or fully differentiated somatic cells derived from the plurality of universal donor cells of claim 14.

### Claim 19 (depends on 18)

The population of cells of claim 18, wherein the lineage-restricted progenitor cells are definitive endoderm cells, primitive gut tube cells, posterior foregut cells, pancreatic endoderm progenitors, pancreatic endocrine progenitors, immature beta cells, or maturing beta cells, and the fully differentiated somatic cells are pancreatic beta cells.

### Claim 20 (depends on 18)

The population of cells of claim 18, wherein at least about 50% of the cells express PD-L1 and/or at least about 50% of the cells express HLA-E.

### Claim 21 (depends on 18)

The population of cells of claim 18, wherein at least about 70% of the cells express PD-L1 and/or at least about 70% of the cells express HLA-E.

### Claim 22 (depends on 18)

The population of cells of claim 18, wherein at least about 90% of the cells express PD-L1 and/or at least about 90% of the cells express HLA-E.

### Claim 23

A genetically modified cell having introduced or increased expression of PD-L1 and HLA-E and disrupted expression of B2M and TXNIP, wherein the genetically modified cell has increased immune evasion and/or cell survival compared to an unmodified cell.

### Claim 24 (depends on 23)

The genetically modified cell of claim 23, comprising a nucleotide sequence encoding PD-L1 inserted within or near a gene encoding B2M, thereby disrupting the B2M gene, and a nucleotide sequence encoding HLA-E inserted within or near a gene encoding TXNIP, thereby disrupting the TXNIP gene.

### Claim 25 (depends on 23)

The genetically modified cell of claim 23, wherein disrupted expression of B2M and TXNIP comprises reduced or eliminated expression of B2M and TXNIP.

### Claim 26 (depends on 14)

A method for treating diabetes in a subject in need thereof, the method comprising:
(a) obtaining or having obtained the plurality of universal donor cells of claim 14 following differentiation into pancreatic endoderm cells, pancreatic endocrine cells, immature beta cells, maturing beta cells, or pancreatic beta cells; and
(b) administering the pancreatic endoderm cells, pancreatic endocrine cells, immature beta cells, maturing beta cells, or pancreatic beta cells to the subject.

### Claim 27 (depends on 26)

The method of claim 26, wherein administering comprises implanting a device comprising the pancreatic endoderm cells, pancreatic endocrine cells, immature beta cells, maturing beta cells, or pancreatic beta cells into the subject.

### Claim 28 (depends on 26)

The method of claim 26, wherein the subject has type I diabetes or type II diabetes.

### Claim 29 (depends on 26)

The method of claim 26, wherein the subject is human.
